Molnupiravir

产品说明书

Print
Chemical Structure| 2492423-29-5 同义名 : -
CAS号 : 2492423-29-5
货号 : A1463646
分子式 : C13H19N3O7
纯度 : 98%
分子量 : 329.306
MDL号 : MFCD32663515
存储条件：

Pure form Sealed in dry,Store in freezer, under -20°C

In solvent -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 50 mg/mL(151.83 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 12 mg/mL(36.44 mM)，配合低频超声助溶
动物实验配方：
生物活性
描述 Molnupiravir (EIDD-2801) is an antiviral medication that inhibits the replication of certain RNA viruses. Molnupiravir has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. Molnupiravir (50-500 mg/kg; p.o.; every 12 hours for 3 days) is robustly antiviral and able to prevent SARS-CoV replication and disease[1]. Molnupiravir (7 mg/kg; p.o.; twice daily for 3.5 days) significantly reduces shed virus load and duration of fever[2]. It has recently been tested in COVID-19. 1600mg daily dose of molnupiravir is safe and tolerable, without any serious adverse events up to 5.5 days, and significantly lower time to clearance (RNA negative) with molnupiravir 800mg twice daily. The study also showed a significant reduction in the risk of hospital admission or death by 50% with the treatment of molnupiravir[3].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.04mL

0.61mL

0.30mL

15.18mL

3.04mL

1.52mL

30.37mL

6.07mL

3.04mL
参考文献

[1]Sheahan TP, Sims AC, Zhou S, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020;12(541):eabb5883.

[2]Toots M, Yoon JJ, Cox RM, et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019;11(515):eaax5866.

[3]Singh AK, Singh A, Singh R, Misra A. Molnupiravir in COVID-19: A systematic review of literature. Diabetes Metab Syndr. 2021;15(6):102329.